Compare Equinix Inc (EQIX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Repligen Corporation Common Stock — how do they compare? Equinix Inc trades at $971.12 (market cap $98.27B), while Repligen Corporation Common Stock trades at $181.78 (market cap $11.31B). The key difference: Equinix Inc is far larger — about 8.7× Repligen Corporation Common Stock's market cap, and Equinix Inc pays a 2.07% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Repligen Corporation Common Stock for 0 Days on average.
| EQIX | RGEN | |
|---|---|---|
Market Cap | $98.27B | $11.31B |
Volume | 450,557 | 1,216,919 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $194.57 |
52-Week Low | $726.09 | $102.87 |
Typical Hold Time | 110 Days | 0 Days |
Enterprise Value | $119.40B | $11.20B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $976.98, down 4.16% on the day, reflecting market volatility despite a bullish technical signal from moving averages. The company reported a net income margin of 15.63% for 2025, with revenue growth to $9.22B, though recent quarters show mixed earnings performance with two misses and one beat. Analyst consensus remains strongly bullish with a $1,250 price target, supported by accelerating AI-driven demand for data center capacity.
The outlook is positive due to robust AI infrastructure investments and a 75% buy rating from analysts, but risks include high valuation multiples (P/E 64.09) and significant capital expenditures, with net cash flow negative $1.26B in 2025. Shareholders face exposure to debt levels rising to 47.13% of assets, potentially pressuring equity returns if growth slows.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
